Compare $BCLI vs $INTS | Chartloom

Compare

$BCLI vs $INTS

Brainstorm Cell Therapeutics Inc · Intensity Therapeutics Inc

BCLI

Brainstorm Cell Therapeutics Inc

INTS

Intensity Therapeutics Inc

Compare $BCLI vs $INTS

Comparing Brainstorm Cell Therapeutics Inc and Intensity Therapeutics Inc

BCLIBrainstorm Cell Therapeutics Inc

INTSIntensity Therapeutics Inc

BCLIBrainstorm Cell Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

54.9%

52W performance

30.1%

FCF yield

-21.1%

INTSIntensity Therapeutics Inc

Market cap

$10M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

-64.3%

52W performance

-49.1%

FCF yield

-91.4%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

BCLI

INTS

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

INTS

Intensity Therapeutics Inc

Market Cap

BCLI$10M

INTS$10M

Enterprise Value

BCLI$12M

INTS$272K

Price

BCLI$0.95

INTS$3.63

P/E Ratio

BCLIN/A

INTSN/A

P/S Ratio

BCLI0.00x

INTS0.00x

EV/Sales

BCLI0.00x

INTS0.00x

EV/EBITDA

BCLI0.00x

INTS0.00x

P/B Ratio

BCLI7.31x

INTS1.22x

P/FCF Ratio

BCLIN/A

INTSN/A

EV/FCF

BCLI-5.29x

INTS-0.03x

PEG Ratio

BCLIN/A

INTSN/A

Forward P/E (NTM)

BCLIN/A

INTSN/A

Forward P/S (NTM)

BCLIN/A

INTSN/A

Revenue (TTM)

BCLI$0

INTS$0

Revenue Growth (YoY)

BCLIN/A

INTSN/A

Forward Rev Growth

BCLI53.7%

INTS506.0%

Gross Margin (TTM)

BCLI0.0%

INTS0.0%

Operating Margin (TTM)

BCLI0.0%

INTS0.0%

EBITDA Margin (TTM)

BCLI0.0%

INTS0.0%

Net Margin (TTM)

BCLI0.0%

INTS0.0%

FCF Margin (TTM)

BCLIN/A

INTSN/A

Net Income (TTM)

BCLI$-7M

INTS$-11M

FCF (TTM)

BCLI$-2M

INTS$-9M

EPS (TTM)

BCLI-$0.61

INTS-$4.12

ROE (TTM)

BCLI-23636.0%

INTS-11661.0%

ROA (TTM)

BCLI-33822.0%

INTS-9401.0%

ROIC (TTM)

BCLI-23636.0%

INTS-11661.0%

Cash

BCLI$22K

INTS$10M

Debt

BCLI$1M

INTS$0

Net Cash/Debt

BCLI$-1M

INTS$10M

Current Ratio (TTM)

BCLI0.21x

INTS5.00x

Quick Ratio (TTM)

BCLI0.16x

INTS4.24x

Debt/Equity (TTM)

BCLI0.00x

INTS0.00x

Debt/Assets (TTM)

BCLI0.0%

INTS0.0%

Interest Coverage (TTM)

BCLIN/A

INTSN/A

Net Debt/EBITDA (TTM)

BCLI0.00x

INTS0.00x

Beta

BCLI0.39

INTS3.02

52W Performance

BCLI30.1%

INTS-49.1%

YTD Performance

BCLI54.9%

INTS-64.3%

% from 52W High

BCLI-43.8%

INTS-91.7%

% from 52W Low

BCLI106.9%

INTS13.1%

Asset Turnover (TTM)

BCLI0.00x

INTS0.00x

FCF Yield (TTM)

BCLI-21.1%

INTS-91.4%

Earnings Yield (TTM)

BCLI-64.2%

INTS-113.9%

Dividend Yield (TTM)

BCLIN/A

INTSN/A

Rule of 40

BCLI0.0

INTS0.0

EV/GP/RG

BCLIN/A

INTSN/A

Ticker research

View BCLI research View INTS research

Metric	BCLI Brainstorm Cell Therapeutics Inc	INTS Intensity Therapeutics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$12M	$272K
Price	$0.95	$3.63
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	1.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	-0.03x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	506.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-7M	$-11M
FCF (TTM)	$-2M	$-9M
EPS (TTM)	-$0.61	-$4.12
ROE (TTM)	-23636.0%	-11661.0%
ROA (TTM)	-33822.0%	-9401.0%
ROIC (TTM)	-23636.0%	-11661.0%
Financial Health
Cash	$22K	$10M
Debt	$1M	$0
Net Cash/Debt	$-1M	$10M
Current Ratio (TTM)	0.21x	5.00x
Quick Ratio (TTM)	0.16x	4.24x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	3.02
52W Performance	30.1%	-49.1%
YTD Performance	54.9%	-64.3%
% from 52W High	-43.8%	-91.7%
% from 52W Low	106.9%	13.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-21.1%	-91.4%
Earnings Yield (TTM)	-64.2%	-113.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BCLI research	View INTS research

Valuation

P/S Ratio

BCLI

0.00x

INTS

0.00x

EV/FCF

BCLI

-5.29x

INTS

-0.03x

Growth & revenue

Forward Revenue Growth

INTS

506.0%

BCLI

53.7%

Profitability & performance

Gross Margin

BCLI

0.0%

INTS

0.0%

ROE

INTS

-11661.0%

BCLI

-23636.0%

FCF Yield %

BCLI

-21.1%

INTS

-91.4%

52-Week Performance

BCLI

30.1%

INTS

-49.1%

Detailed metrics comparison

BCLI

Brainstorm Cell Therapeutics Inc

INTS

Intensity Therapeutics Inc

Market Cap

BCLI$10M

INTS$10M

Enterprise Value

BCLI$12M

INTS$272K

Price

BCLI$0.95

INTS$3.63

P/E Ratio

BCLIN/A

INTSN/A

P/S Ratio

BCLI0.00x

INTS0.00x

EV/Sales

BCLI0.00x

INTS0.00x

EV/EBITDA

BCLI0.00x

INTS0.00x

P/B Ratio

BCLI7.31x

INTS1.22x

P/FCF Ratio

BCLIN/A

INTSN/A

EV/FCF

BCLI-5.29x

INTS-0.03x

PEG Ratio

BCLIN/A

INTSN/A

Forward P/E (NTM)

BCLIN/A

INTSN/A

Forward P/S (NTM)

BCLIN/A

INTSN/A

Revenue (TTM)

BCLI$0

INTS$0

Revenue Growth (YoY)

BCLIN/A

INTSN/A

Forward Rev Growth

BCLI53.7%

INTS506.0%

Gross Margin (TTM)

BCLI0.0%

INTS0.0%

Operating Margin (TTM)

BCLI0.0%

INTS0.0%

EBITDA Margin (TTM)

BCLI0.0%

INTS0.0%

Net Margin (TTM)

BCLI0.0%

INTS0.0%

FCF Margin (TTM)

BCLIN/A

INTSN/A

Net Income (TTM)

BCLI$-7M

INTS$-11M

FCF (TTM)

BCLI$-2M

INTS$-9M

EPS (TTM)

BCLI-$0.61

INTS-$4.12

ROE (TTM)

BCLI-23636.0%

INTS-11661.0%

ROA (TTM)

BCLI-33822.0%

INTS-9401.0%

ROIC (TTM)

BCLI-23636.0%

INTS-11661.0%

Cash

BCLI$22K

INTS$10M

Debt

BCLI$1M

INTS$0

Net Cash/Debt

BCLI$-1M

INTS$10M

Current Ratio (TTM)

BCLI0.21x

INTS5.00x

Quick Ratio (TTM)

BCLI0.16x

INTS4.24x

Debt/Equity (TTM)

BCLI0.00x

INTS0.00x

Debt/Assets (TTM)

BCLI0.0%

INTS0.0%

Interest Coverage (TTM)

BCLIN/A

INTSN/A

Net Debt/EBITDA (TTM)

BCLI0.00x

INTS0.00x

Beta

BCLI0.39

INTS3.02

52W Performance

BCLI30.1%

INTS-49.1%

YTD Performance

BCLI54.9%

INTS-64.3%

% from 52W High

BCLI-43.8%

INTS-91.7%

% from 52W Low

BCLI106.9%

INTS13.1%

Asset Turnover (TTM)

BCLI0.00x

INTS0.00x

FCF Yield (TTM)

BCLI-21.1%

INTS-91.4%

Earnings Yield (TTM)

BCLI-64.2%

INTS-113.9%

Dividend Yield (TTM)

BCLIN/A

INTSN/A

Rule of 40

BCLI0.0

INTS0.0

EV/GP/RG

BCLIN/A

INTSN/A

Ticker research

View BCLI research View INTS research

Metric	BCLI Brainstorm Cell Therapeutics Inc	INTS Intensity Therapeutics Inc
Market & Valuation
Market Cap	$10M	$10M
Enterprise Value	$12M	$272K
Price	$0.95	$3.63
P/E Ratio	N/A	N/A
P/S Ratio	0.00x	0.00x
EV/Sales	0.00x	0.00x
EV/EBITDA	0.00x	0.00x
P/B Ratio	7.31x	1.22x
P/FCF Ratio	N/A	N/A
EV/FCF	-5.29x	-0.03x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	N/A
Revenue & Growth
Revenue (TTM)	$0	$0
Revenue Growth (YoY)	N/A	N/A
Forward Rev Growth	53.7%	506.0%
Profitability
Gross Margin (TTM)	0.0%	0.0%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	0.0%
Net Margin (TTM)	0.0%	0.0%
FCF Margin (TTM)	N/A	N/A
Net Income (TTM)	$-7M	$-11M
FCF (TTM)	$-2M	$-9M
EPS (TTM)	-$0.61	-$4.12
ROE (TTM)	-23636.0%	-11661.0%
ROA (TTM)	-33822.0%	-9401.0%
ROIC (TTM)	-23636.0%	-11661.0%
Financial Health
Cash	$22K	$10M
Debt	$1M	$0
Net Cash/Debt	$-1M	$10M
Current Ratio (TTM)	0.21x	5.00x
Quick Ratio (TTM)	0.16x	4.24x
Debt/Equity (TTM)	0.00x	0.00x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.39	3.02
52W Performance	30.1%	-49.1%
YTD Performance	54.9%	-64.3%
% from 52W High	-43.8%	-91.7%
% from 52W Low	106.9%	13.1%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.00x
FCF Yield (TTM)	-21.1%	-91.4%
Earnings Yield (TTM)	-64.2%	-113.9%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	0.0
EV/GP/RG	N/A	N/A
Ticker research	View BCLI research	View INTS research